Latest Content

Duke Blood Cancer Center's Melissa LaMirand, FNP-C, discusses quad therapies, bispecific workflows, and nursing standardization in multiple myeloma.

Emily M. Beard, BSN, RN, OCN, CBCN, BHCN, discusses the vital role of oncology nurse navigation in addressing barriers to care and improving outcomes in cancer survivorship.

FDA approves Tudriqev-nivolumab for advanced melanoma. Learn key clinical trial data, dosing math, and safety rules for oncology nursing teams.

A social worker explains how patient "difficulties" are often trauma-based fight, flight, freeze, or fawn responses to a health crisis.

Dr. Michael Wong discusses clinical workflows, dosing calculations, and biosafety protocols for the newly approved Tudriqev-nivolumab regimen.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses patient compliance, side effect management, and screening anxiety in breast cancer care.

A new study reveals global gaps in integrative oncology knowledge, highlighting communication and the role of APPs in community settings.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

FDA approves Tudriqev with nivolumab for advanced cutaneous melanoma. Learn about dosing, safety warnings, and trial data for oncology nurses.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses managing the influx of new breast cancer therapies and the importance of professional networking.

New research shows high-dose oral vitamin D provides rapid relief for chemo-induced erythema and radiation dermatitis without toxicity.

Oncology nurses must differentiate cyclospora from treatment side effects and use PCR-based GI panels to ensure rapid diagnosis during the outbreak.

Oncology nurse Pattie Jakel shares her story of ILC recurrence, highlighting why MRI and specialized education are vital for lobular breast cancer.